statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

It is a pleasure to report that the Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) is up 99% in the last quarter. But...

Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders are up 18% this past week, but still in the red over the last three years

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with...

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Adaptimmune Therapeutics plc (NASDAQ:ADAP  Get Free Report) fell 2.1% on Tuesday . The company traded as low as $1.41 and last traded at $1.41. 62,343 shares were traded during trading, a...

Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 2.1%

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Adaptimmune Therapeutics (ADAP Research Report), Elevation Oncology...

Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)

Key Financial Highlights and Business UpdatesRelated Stocks: ADAP...

Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results

Adaptimmune Therapeutics (ADAP Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy...

Buy Rating Affirmed for Adaptimmune on Upcoming Milestones and Promising Trial Results

U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024Confirmatory evidence for afami-cel full approval agreed...

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Adaptimmune Therapeutics plc (NASDAQ:ADAP  Get Free Report) was the recipient of a large decrease in short interest in the month of February. As of February 15th, there was short interest...

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Sees Large Decrease in Short Interest

Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc...

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP  Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $1.38, but opened at $1.45. Adaptimmune...

Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $1.38

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Volume	565,527.00
52-Wk High	$2.05
52-Wk Low	$0.42

ADAP Adaptimmune Therapeutics

About

Feed

News

Sentiment

Earnings

Fundamentals